HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BS 1417

an angiogenesis inhibitor

Also Known As:

BS-1417; BS1417

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - BS 1417: 2

Experts

1.	Honda, Shigeru: 1 article (04/2009)
2.	Nagai, Takayuki: 1 article (04/2009)
3.	Negi, Akira: 1 article (04/2009)
4.	Fukuya, Fumiyo: 1 article (07/2005)
5.	Honda, Yayoi: 1 article (07/2005)
6.	Iwama, Seiji: 1 article (07/2005)
7.	Kitano, Tomoko: 1 article (07/2005)
8.	Morie, Toshiya: 1 article (07/2005)
9.	Notake, Mitsue: 1 article (07/2005)
10.	Sato, Yuji: 1 article (07/2005)

Related Diseases

1.	Neointima 07/01/2005 - "Although withdrawal of treatment with BS-1417 after short-term administration after injury resulted in catch-up growth of neointima, a long-term study suggested that this catch-up growth can be prevented by continuous administration of BS-1417 until EC regeneration. " 07/01/2005 - "Subcutaneous infusion of BS-1417 for 2, 4, 7, or 12 weeks after injury potently inhibited neointima formation without affecting EC regeneration. " 07/01/2005 - "We clarified that alphavbeta3 integrin and EC regeneration play an essential role in neointima formation, and that continuous administration of BS-1417 potently and stably inhibits neointima formation without affecting EC regeneration. "
2.	Choroidal Neovascularization 04/01/2009 - "To evaluate the anti-angiogenic effects of integrin alphavbeta3 specific antagonist BS-1417 on laser-induced choroidal neovascularization (CNV) in mice. "

Related Drugs and Biologics

1.	Integrin alphaVbeta3

Related Therapies and Procedures

1.	Subcutaneous Infusions
2.	Lasers (Laser)